1. Home
  2. BATL vs NXL Comparison

BATL vs NXL Comparison

Compare BATL & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Battalion Oil Corporation

BATL

Battalion Oil Corporation

HOLD

Current Price

$1.19

Market Cap

20.1M

Sector

Energy

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.93

Market Cap

18.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATL
NXL
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.1M
18.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
BATL
NXL
Price
$1.19
$0.93
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
79.3K
113.8K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$183,422,000.00
$156,931.00
Revenue This Year
N/A
$38.28
Revenue Next Year
N/A
$185.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.70
52 Week High
$3.67
$4.19

Technical Indicators

Market Signals
Indicator
BATL
NXL
Relative Strength Index (RSI) 47.28 37.05
Support Level $1.15 $0.93
Resistance Level $1.25 $1.01
Average True Range (ATR) 0.05 0.06
MACD 0.00 0.00
Stochastic Oscillator 27.60 6.76

Price Performance

Historical Comparison
BATL
NXL

About BATL Battalion Oil Corporation

Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: